Comparison of human saliva and synthetic histo-blood group antigens usage as ligands in norovirus-like particle binding and blocking assays

Microbes and Infection

Volumn 16, Issue 6, 2014, Pages 472-480

  Uusi Kerttula, Hanni ^a   Tamminen, Kirsi ^a   Malm, Maria ^a   Vesikari, Timo ^a,b   Blazevic, Vesna ^a  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Ligand binding; Neutralization; Norovirus; Virus like particle

Indexed keywords

BLOOD GROUP ANTIGEN; LIGAND; SIALYL LEWIS X ANTIGEN; ANTISERUM; CARBOHYDRATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; NOROVIRUS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SALIVA; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; GENOTYPE; MOUSE; VIRION; VIRUS ATTACHMENT;

MIRIDAE; NOROVIRUS;

ANIMALS; BLOOD GROUP ANTIGENS; CARBOHYDRATES; FEMALE; GENOTYPE; HUMANS; IMMUNE SERA; LIGANDS; MICE; MICE, INBRED BALB C; SALIVA; VIRION; VIRUS ATTACHMENT;

EID: 84902762929     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2014.02.010     Document Type: Article

References (36)

1. Glass R.I., Parashar U.D., Estes M.K. Norovirus gastroenteritis. N Engl J Med 2009, 361:1776-1785. 1726.
2. Duizer E., Schwab K.J., Neill F.H., Atmar R.L., Koopmans M.P.G., Estes M.K. Laboratory efforts to cultivate noroviruses. J Gen Virol 2004, 85:79-87.
3. Jiang X., Wang M., Graham D.Y., Estes M.K. Expression, self-assembly and antigenicity of the Norwalk virus capsid protein. J Virol 1992, 66:6527-6532.
4. Ravn V., Dabelsteen E. Tissue distribution of histo-blood group antigens. Apmis 2000, 108:1-28.
5. Harrington P.R., Lindesmith L., Yount B., Moe C.L., Baric R.S. Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol 2002, 76:12335-12343.
6. Hutson A.M., Atmar R.L., Graham D.Y., Estes M.K. Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis 2002, 185:1335-1337.
7. Marionneau S., Ruvoën N., Le Moullac-Vaidye B., Clement M., Cailleau-Thomas A., Ruiz-Palacois G., et al. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology 2002, 122:1967-1977.
8. Hutson A.M., Atmar R.L., Estes M.K. Norovirus disease: changing epidemiology and host susceptibility factors. Trends Microbiol 2004, 12:279-287.
9. Tan M., Jiang X. Norovirus and its histo-blood group antigen receptors: an answer to a historical puzzle. Trends Microbiol 2005, 13:285-293.
10. Donaldson E.F., Lindesmith L.C., Lobue A.D., Baric R.S. Viral shape-shifting: norovirus evasion of the human immune system. Nat Rev Microbiol 2010, 83:231-241.
11. LoBue A.D., Lindesmith L., Yount B., Harrington P.R., Thompson J.M., Johnston R.E., et al. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 2006, 24:5220-5234.
12. Reeck A., Kavanagh O., Estes M.K., Opekun A.R., Gilger M.A., Graham D.Y., et al. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 2010, 202:1212-1218.
13. Nurminen K., Blazevic V., Huhti L., Räsänen S., Koho T., Hytönen V.P., et al. Prevalence of norovirus GII-4 antibodies in Finnish children. J Med Virol 2011, 83:525-531.
14. Frenck R., Bernstein D.I., Xia M., Huang P., Zhong W., Parker S., et al. Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans. J Infect Dis 2012, 206:1386-1393.
15. Lindesmith L.C., Donaldson E.F., LoBue A.D., Cannon J.L., Zheng D., Vinje J., et al. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med 2008, 5:269-290.
16. Lindesmith L.C., Debbink K., Swanstrom J., Vinjé J., Costantini V., Baric R.S., et al. Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J Virol 2012, 86:873-883.
17. Debbink K., Lindesmith L.C., Donaldson E.F., Costantini V., Beltramello M., Corti D., et al. Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J Infect Dis 2013, 208:1877-1887.
18. Lindesmith L.C., Costantini V., Swanstrom J., Debbink K., Donaldson E.F., Vinjé J., et al. Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J Virol 2013, 87:2803-2813.
19. Siebenga J.J., Vennema H., Zheng D., Vinjé J., Bonita E., Lee X.-P., et al. Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001-2007. J Infect Dis 2009, 200:802-812.
20. Puustinen L., Blazevic V., Salminen M., Hämäläinen M., Räsänen S., Vesikari T. Noroviruses as a major cause of acute gastroenteritis in children in Finland, 2009-2010. Scand J Infect Dis 2011, 43:804-808.
21. Puustinen L., Blazevic V., Huhti L., Szakal E.D., Halkosalo A., Salminen M., et al. Norovirus genotypes in endemic acute gastroenteritis of infants and children in Finland between 1994 and 2007. Epidemiol Infect 2012, 140:268-275.
22. Adler J.L., Zickl R. Winter vomiting disease. J Infect Dis 1969, 119:668-673.
23. Huhti L., Blazevic V., Nurminen K., Koho T., Hytönen V.P., Vesikari T. A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles. Arch Virol 2010, 155:1855-1858.
24. Blazevic V., Lappalainen S., Nurminen K., Huhti L., Vesikari T. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine 2011, 29:8126-8133.
25. Huhti L., Tamminen K., Vesikari T., Blazevic V. Characterization and immunogenicity of norovirus capsid-derived virus-like particles purified by anion exchange chromatography. Arch Virol 2013, 158:933-942.
26. Tamminen K., Huhti L., Koho T., Lappalainen S., Hytönen V.P., Vesikari T., et al. A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles. Immunology 2012, 135(1):89-99.
27. Huang P., Farkas T., Marionneau S., Zhong W., Ruvoën-Clouet N., Morrow A.L., et al. Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns. J Infect Dis 2003, 188:19-31.
28. Huflejt M.E., Vuskovic M., Vasiliu D., Xu H., Obukhova P., Shilova N., et al. Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. Mol Immunol 2009, 46:3037-3049.
29. Lindesmith L.C., Donaldson E., Leon J., Moe C.L., Frelinger J.A., Johnston R.E., et al. Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol 2010, 844:1800-1815.
30. Hansman G.S., Biertümpfel C., Georgiev I., McLellan J.S., Chen L., Zhou T., et al. Crystal structures of GII.10 and GII.12 norovirus protruding domains in complex with histo-blood group antigens reveal details for a potential site of vulnerability. J Virol 2011, 85:6687-6701.
31. Vega E., Vinjé J. Novel GII.12 norovirus strain, United States, 2009-2010. Emerg Infect Dis 2011, 17:1516-1518.
32. Lindesmith L.C., Beltramello M., Donaldson E.F., Corti D., Swanstrom J., Debbink K., et al. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog 2012, 8:e1002705.
33. Tian P., Engelbrektson A., Mandrell R. Two-log increase in sensitivity for detection of norovirus in complex samples by concentration with porcine gastric mucin conjugated to magnetic beads. Appl Environ Microbiol 2008, 74:4271-4276.
34. Huang P., Farkas T., Zhong W., Tan M., Thornton S., Morrow A.L., et al. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol 2005, 79:6714-6722.
35. Tan M., Xia M., Chen Y., Bu W., Hedge R.S., Meller J., et al. Conservation of carbohydrate binding interfaces - evidence of human HBGA selection in norovirus evolution. PLoS One 2009, 4:e5058.
36. Tamminen K., Huhti L., Vesikari T., Blazevic V. Pre-existing immunity to norovirus GII-4 virus-like particles does not impair de novo immune responses to norovirus GII-12 genotype. Viral Immunol 2013, 26:167-170.